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Abstract: Esophageal adenocarcinoma (EAC) is a highly lethal cancer type with an overall poor
survival rate. Twenty to thirty percent of EAC overexpress the human epidermal growth factor
receptor 2 (Her2), a transmembrane receptor tyrosine kinase promoting cell growth and proliferation.
Patients with Her2 overexpressing breast and gastroesophageal cancer may benefit from Her2
inhibitors. Therapy resistance, however, is well documented. Since autophagy, a lysosome-dependent
catabolic process, is implicated in cancer resistance mechanisms, we tested whether autophagy
modulation influences Her2 inhibitor sensitivity in EAC. Her2-positive OE19 EAC cells showed
an induction in autophagic flux upon treatment with the small molecule Her2 inhibitor Lapatinib.
Newly generated Lapatinib-resistant OE19 (OE19 LR) cells showed increased basal autophagic
flux compared to parental OE19 (OE19 P) cells. Based on these results, we tested if combining
Lapatinib with autophagy inhibitors might be beneficial. OE19 P showed significantly reduced cell
viability upon double treatment, while OE19 LR were already sensitive to autophagy inhibition alone.
Additionally, Her2 status and autophagy marker expression (LC3B and p62) were investigated in
a treatment-naïve EAC patient cohort (n = 112) using immunohistochemistry. Here, no significant
correlation between Her2 status and expression of LC3B and p62 was found. Our data show that
resistance to Her2-directed therapy is associated with a higher basal autophagy level, which is not
per se associated with Her2 status. Therefore, we propose that autophagy may contribute to acquired
resistance to Her2-targeted therapy in EAC, and that combining Her2 and autophagy inhibition
might be beneficial for EAC patients.
Keywords: autophagy; Her2; Lapatinib; LC3B; p62; OE19; Her2 inhibitor; resistance;
esophageal adenocarcinoma
1. Introduction
Esophageal adenocarcinoma (EAC) is a highly aggressive malignant disease. Locally advanced
tumors without distant metastases are treated with peri- or preoperative chemo(radio)therapy and
surgery, while patients with metastatic disease can only benefit from palliative chemotherapy [1].
In both clinical scenarios, the high rate of resistance to chemotherapy or radiochemotherapy limits
the success of the treatment and thus the survival rate for EAC patients remains low [2]. Therefore,
alternative therapeutic options targeting molecular alterations in EAC are in high demand.
Int. J. Mol. Sci. 2018, 19, 3069; doi:10.3390/ijms19103069 www.mdpi.com/journal/ijms
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Gene amplifications of the human epidermal growth factor receptor 2 (Her2) are reported in
20–30% of EAC cases [3]. It is an oncogenic driver that signals for proliferation and survival. At
present, humanized Her2-targeting monoclonal antibody trastuzumab/Herceptin has been approved
for the treatment of metastatic Her2-positive gastric cancer and cancers of the gastroesophageal
junction [4]. Accordingly, Her2-positive EAC can be treated off-label with Herceptin [5]. A second class
of Her2-targeting drugs consists of receptor tyrosine kinase (RTK) small molecule inhibitors such as
Lapatinib. Her2-targeting small molecule inhibitors prevent phosphorylation of Her2 by competitively
binding to the ATP-binding pocket and in turn prevent oncogenic downstream signaling pathways [6].
Although approved for treatment of Her2-positive metastatic breast cancer, Lapatinib has performed
poorly in clinical trials pertaining to gastric cancer, possibly due to heterogeneity, low thresholds
of Her2 positivity, and overlapping toxicity profiles with other drugs in combination treatments.
Nevertheless, Her2 targeting is still a clinically important therapeutic option which warrants extensive
investigation [7].
Macroautophagy (abbreviated here as autophagy) is an evolutionarily conserved
lysosome-dependent cellular process. Under basal conditions, autophagy maintains cellular
homeostasis by degrading damaged or superfluous organelles and proteins and recycling sugars,
amino and fatty acids, as well as nucleotides. Generally, autophagy is a prosurvival mechanism
upregulated upon cellular stresses such as nutrient deprivation, metabolic/oxidative stress, or
infection [8,9]. In the context of cancer, autophagy has been described as being oncosuppressive as well
as oncogenic. In the setting of established tumors, autophagy is thought to maintain cancer stem cells
as well as dormant or senescent transformed cancer cells, which is in contrast to its oncosuppresive
functions in early stages, where the process maintains normal stem cells. Furthermore, autophagy
confers survival advantages to cancer cells under various kinds of antitumoral treatment [10,11].
Her2 signaling and autophagy are linked via the main negative regulator of autophagy, mTORC1,
which is downstream of Her2 [12]. In breast cancer, increased autophagic flux has been attributed
to resistance to both monoclonal Her2-targeting antibodies and small molecule inhibitors in vitro as
well as in vivo [13–15]. Moreover, pharmacological or genetic inhibition of autophagy was successful
in resensitizing breast cancer cells to Her2-targeted therapy. However, in line with the dual role of
autophagy in cancer, contradictory results also have been reported [16]. As intrinsic and acquired
resistance to Her2-targeted therapy is well documented in different cancer types, investigating the role
of autophagy in Her2-targeted therapeutic response in gastroesophageal cancer could be of clinical
relevance. More importantly, routine diagnosis and treatment of Her2-positive EAC cases are realistic
in the future [17].
We quantified autophagy regulation upon Her2-targeted therapy using the RTK small molecule
inhibitor Lapatinib in OE19 EAC cells. Furthermore, we investigated the potential role of autophagy
in acquired resistance against Her2-targeted therapy in EAC in vitro. Moreover, we tested whether
the combination treatment of Her2 and autophagy inhibitors is beneficial in treating parental and
Lapatinib-resistant OE19 cells. Lastly, in order to investigate a potential intrinsic association between
Her2 and autophagy in EAC, we compared the Her2 status with the basal expression of autophagy
markers in an EAC patient cohort ex vivo in a treatment-naïve setting.
2. Results
2.1. Validation of Lapatinib Sensitivity and Her2 Status of OE19 Cells
We used the Her2-positive EAC cell line OE19, as OE19 cells have already been characterized as
sensitive to Her2 inhibition. Due to the cell line’s low threshold for Lapatinib, the concentrations used
for functional assays in published studies often exceed the IC50 value [18,19]. For this purpose, we
tested the responsiveness of OE19 to Lapatinib in house and optimized the working concentrations
for autophagy and cell viability assays in order to minimize the chance that observed experimental
results are attributed to off-target effects. The resazurin-reduction-based alamarBlue® assay was
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used to determine the relative toxicity of different Lapatinib concentrations on OE19 (Figure S1a). To
assess whether the decreased cell viability observed via alamarBlue® assay was due to apoptosis, the
luminescence-based Caspase-Glo® 3/7 assay was used. OE19 were treated with the same range of
Lapatinib for 24 h and the activity of the caspases 3 and 7 was measured (Figure S1b). Based on these
results, we chose 120 nM of Lapatinib as the working concentration. We considered this concentration
appropriate for autophagy assays as well as for experiments with combination treatments.
The Her2 status of different EAC cell lines has been described in the literature, and among them,
OE19 has been characterized as Her2 positive [19,20]. The methods used to confirm Her2 amplification,
however, included array-based comparative genome hybridization (CGH) and varied between studies.
Therefore, we validated Her2 status using FISH and immunohistochemistry (IHC) methods used for
routine diagnostics of breast and gastroesophageal cancer and which have been tested and validated
on EAC patient tissue [21]. In line with the published data, we observed a Her2 amplification in OE19
cells via FISH, with corresponding increased levels of protein observed via IHC score 3+ (Figure S1c,d).
2.2. Induction of Autophagic Flux in OE19 Cells upon Lapatinib Treatment
We then set out to find out whether Lapatinib treatment leads to an upregulation of autophagic
flux in OE19 cells. The autophagic flux was assessed via LC3B Western blotting. We compared
autophagy in blocked and nonblocked conditions of Lapatinib-treated as well as Lapatinib-untreated
cells. To block autophagy, BafilomycinA (BafA), a late-stage autophagy inhibitor, was added. As a
control for successful Lapatinib treatment, we also checked levels of Phospho-Her2 (Figure 1a). The
autophagic flux was calculated (BafA+-BafA− conditions) (Figure 1b). In this experiment, we observed
an approximative 50% increase in autophagic flux upon Lapatinib treatment. To corroborate this
observation, we assessed the autophagic flux using an mCherry-EGFP-LC3 construct and FACS
analysis. Upon fusion of the autophagosome with the lysosome, the green fluorescence of the
mCherry-EGFP-LC3 construct is quenched due to the lower pH in the autolysosome that leads to a
shift to red fluorescence [22]. Using this technique, we observed a significant induction of autophagic
flux in OE19 cells upon Lapatinib treatment (Figure 1c,d). BafA-treated OE19 cells were included as
a control.
Together, using two LC3-based methods, we could show that Lapatinib treatment leads to an
induction of autophagic flux in OE19 cells.
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Figure 1. Induction of autophagic flux in OE19 upon Lapatinib treatment. (a) LC3B flux was assessed 
comparing control and BafilomycinA (BafA)-treated (200 nM, 2 h) OE19 upon Lapatinib treatment 
(120 nM, 24 h). LC3 band intensities were quantified using ImageJ software. Total protein was used 
as a loading control, and Phospho-Her2 for Lapatinib treatment (n = 3). (b) LC3B flux was calculated 
from data in (a) as follows: BafA+-BafA− values for each condition. (c) FACS analysis of mCherry-
EGFP-LC3B-expressing OE19 cells upon induction or blockade of autophagy with indication of the 
chosen cut-off value for high respectively low autophagic flux. (d) Quantification of the FACS analysis 
showing % of cells with high autophagic flux (n = 3). Cells were treated as in (a). The error bars 
represent SD, statistical significance was determined by Mann–Whitney U test: * p ≤ 0.05, ** p ≤ 0.01. 
2.3. Her2-Inhibition-Resistant OE19 Daughter Cells Show Increased Autophagic Activity Compared to Their 
Normal Counterparts 
In the next step, we generated a Lapatinib-resistant OE19 subline by treating OE19 parental cells 
(OE19 P) with increasing concentrations of Lapatinib (up to 120 nM) for at least 3 months. Finally, we 
cultured the cells with 120 nM of Lapatinib to preserve the resistant pool of OE19 cells (OE19 LR). In 
Figure 2a, an alamarBlue® assay is depicted comparing the relative cell viability of OE19 P and OE19 
LR under Lapatinib treatment. 
We used the mCherry-EGFP-LC3 construct and FACS analysis to compare the autophagic flux 
induction in these two cell lines upon Lapatinib treatment. We observed a significantly higher basal 
autophagic flux in OE19 LR compared to OE19 P cells. Moreover, Lapatinib treatment resulted in a 
significant induction of flux in both lines (Figure 2b). In addition, we used a VPS34 kinase inhibitor 
(VPS34-IN1), a novel, early stage autophagy inhibitor [23]. Using this inhibitor, both cell lines 
responded by showing significantly decreased basal autophagy levels. The combination of VPS34-
IN1 with Lapatinib led to a reduction of autophagy back to basal autophagy activity (Figure 2b). 
Taken together, we observed that OE19 LR cells show significantly increased basal autophagy. 
Moreover, Lapatinib-induced autophagy can be blocked by a specific autophagy inhibitor 
inactivating VPS34 kinase. 
Figure 1. Induction of autophagic flux in OE19 upon Lapatinib treatment. (a) LC3B flux was assessed
comparing control and BafilomycinA (BafA)-treated (200 nM, 2 h) OE19 upon Lapatinib treatment
(120 nM, 24 h). LC3 band intensities were quantified using ImageJ software. Total protein was
used as a loading control, and Phospho-Her2 for Lapatinib treatment (n = 3). (b) LC3B flux was
calculated from data in (a) as follows: BafA+-BafA− values for each condition. (c) FACS analysis of
mCherry-EGFP-LC3B-expressing OE19 cells upon induction or blockade of autophagy with indication
of the chosen cut-off value for high respectively low autophagic flux. (d) Quantification of the FACS
analysis showing % of cells with high autophagic flux (n = 3). Cells were treated as in (a). The error bars
represent SD, statistical significance was determined by Mann–Whitney U test: * p ≤ 0.05, ** p ≤ 0.01.
2.3. Her2-Inhibition-Resistant OE19 Daughter Cells Show Increased Autophagic Activity Compared to Their
Normal Counterparts
In the next step, we generated a Lapatinib-resistant OE19 subline by treating OE19 parental cells
(OE19 P) with incr a ing concentrations of Lapatinib (up to 120 nM) for at least 3 months. Finally, we
cultured the cells with 120 nM of Lapatinib to prese ve sistant pool of OE19 cells (OE19 LR). In
Figure 2a, an alamarBlue® assay is depicted comparing the relative cell viability of OE19 P and OE19
LR under Lapatinib treatment.
We used the mCherry-EGFP-LC3 construct and FACS analysis to compare the autophagic flux
induction in these two cell lines upon Lapatinib treatment. We observed a significantly higher basal
autophagic flux in OE19 LR compared to OE19 P cells. Moreover, Lapatinib treatment resulted
in a significant induction of flux in both lines (Figure 2b). In addition, we used a VPS34 kinase
inhibitor (VPS34-IN1), a novel, early stage autophagy inhi itor [23]. Using this inhibitor, both
cell lines respond d by showing significantly d creased basal autophagy levels. The c mbination
of VPS34-IN1 with Lapatinib led to a reduction of autophag back to basal autophagy activity
(Figure 2b). Taken together, we observed that OE19 LR cells show significantly increased basal
autophagy. Moreover, Lapatinib-induced autophagy can be blocked by a specific autophagy inhibitor
inactivating VPS34 kinase.
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Figure 2. Comparison of the autophagic flux induction in parental (OE19 P) and Lapatinib-resistant 
(OE19 LR) OE19 cells. (a) Relative cell viability assessed by alamarBlue® assay of OE19 P and OE19 
LR cells, treated with dimethyl sulfoxide (DMSO) alone or 120nM of Lapatinib (n = 3). (b) 
Quantification of FACS analysis comparing OE19 P and OE19 LR transduced with a mCherry-EGFP-
LC3B construct (same treatment as in a). As a control, autophagy blocked conditions (addition of 5µM 
VPS34-IN1) were included, (n = 4). The error bars represent SD, statistical significance was determined 
by Mann–Whitney U test: * p ≤ 0.05, ** p ≤ 0.01. 
2.4. Blocking Autophagy in Combination with Her2 Inhibition Significantly Reduces OE19 Cell Viability 
and Colony Formation 
Since we observed that OE19 LR showed significantly higher basal autophagy compared to 
OE19 P cells, we tested whether combining Lapatinib with autophagy inhibitors would resensitize 
the resistant cells. For these experiments, we used the previously described VPS34 inhibitor as well 
as chloroquine (CQ), which is used in the clinic not only for malaria treatment but also for cancer 
therapy, partly in combination regimens with standard cytotoxic chemotherapies [24]. 
In the parental OE19 P cells, inhibiting autophagy alone (VPS34-IN1 or CQ) showed no 
significant effect on the relative cell viability. However, the combination treatments showed a 
significant further reduction in cell viability compared to the single Lapatinib treatment. Differently, 
the effect of the autophagy inhibitor treatments alone as well as the combination with Lapatinib 
showed comparably significant effects on the Lapatinib-resistant OE19 LR cells (Figures 3a and S2). 
In line with the cell viability assays, autophagy inhibition showed no effect in the parental cell 
line, while the double treatment with Lapatinib reduced the cell numbers significantly compared to 
Lapatinib treatment alone. In OE19 LR, inhibition of autophagy with the more specific inhibitor 
(VPS34-IN1) resulted in a significant reduction in cell numbers, whereas this effect was not seen using 
chloroquine. Combining Lapatinib with either autophagy inhibitor resulted in a significant reduction 
of viable OE19 LR cells (Figure 3b). 
Additionally, we performed colony formation assays to address tumor cell recovery. After 48 h 
of treatment, cells were reseeded in very small numbers (identical for all conditions), and after an 
incubation of 14 days without treatment, the colonies were counted. Treating Lapatinib-sensitive 
Figure 2. Comparison of the autophagic flux induction in parental (OE19 P) and Lapatinib-resistant
(OE19 LR) OE19 cells. (a) Relative cell viability assessed by alamarBlue® assay of OE19 P and OE19 LR
cells, treated with dimethyl sulfoxide (DMSO) alone or 120nM of Lapatinib (n = 3). (b) Quantification
of FACS analysis comparing OE19 P and OE19 LR transduced with a mCherry-EGFP-LC3B construct
(same treatment as in a). As a control, autophagy blocked conditions (addition of 5µM VPS34-IN1) were
included, (n = 4). The error bars represent SD, statistical significance was determined by Mann–Whitney
U test: * p ≤ 0.05, ** p ≤ 0.01.
2.4. Blocking Autophagy in Combination with Her2 Inhibition Significantly Reduces OE19 Cell Viability and
Colony Formation
Since we observed that OE19 LR showed significantly higher basal autophagy compared to OE19
P cells, we tested whether combining Lapatinib with aut phagy inhibitors would resensitize the
resistant cells. For these exper ments, we used the previously described VPS34 inhibitor s well as
chloroquine (CQ), which is used in the clinic not o ly for malaria tr atment but also for cancer therapy,
partly in combination regimens with standard cytotoxic chemotherapies [24].
In the parental OE19 P cells, inhibiting autophagy alone (VPS34-IN1 or CQ) showed no significant
effect on the relative cell viability. However, the combination treatments showed a significant further
reduction in cell viability compared to the single Lapatinib treatment. Differently, the effect of the
autophagy inhibitor treatments alone as well as the combination with Lapatinib showed comparably
significant effects on the Lapatinib-resistant OE19 LR cells (Figure 3a and Figure S2).
In line with the cell viability assays, autophagy inhibition showed no eff ct in the parental cell
line, while the doubl treatment wi h Lapatinib reduced the cell numb rs significantly compared
to Lapatinib tr atment alone. In OE19 LR, inhibition of autophagy with the more specific inhibitor
(VPS34-IN1) resulted in a significant reduction in cell numbers, whereas this effect was not seen using
chloroquine. Combining Lapatinib with either autophagy inhibitor resulted in a significant reduction
of viable OE19 LR cells (Figure 3b).
Additionally, we performed colony formation assays to address tumor cell recovery. After 48 h
of treatment, cells were reseeded in very small numbers (identical for all conditions), and after an
incubation of 14 days without treatment, the colonies were counted. Treating Lapatinib-sensitive OE19
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P with Lapatinib alone or in combination with autophagy inhibitors resulted in a significant reduction
in colonies compared to the control conditions. Interestingly, treatment of OE19 LR with Lapatinib and
the VPS34 inhibitor caused a significant reduction in colony numbers, while all other conditions did
not show any significant reduction (Figure 3c and Figure S3).
In summary, our results indicate that blocking autophagy in combination with Lapatinib in OE19
EAC cells showed significantly better treatment effects than Lapatinib treatment alone. Moreover,
combining autophagy and Her2 inhibition allowed the successful treatment of Lapatinib-resistant
EAC cells. Importantly, likely based on the increased basal autophagy of OE19 LR cells, these cells
respond to autophagy inhibition alone under certain conditions.
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Figure 3. Combined Her2 and autophagy inhibit t ent (a) Relative cell v ability of OE19 cells
treated with Lapatinib (120 nM) and/or autophagy inhibition either VPS34 inhibitor ( -I ) ( µM)
or chloroquine (CQ) (25 µM) at days 0 and 3 of the alamarBlue® experi ent (n ≥ 3). (b) Cell counts
of OE19 P and OE19 LR cells treated as in (a) but for 48 h. Values were normalized to DMSO control
treated cells (n = 7) (c) Colony numbers after treatment as described in (b), reseeded (2500 cells/well)
in six-well plates and incubation for 14 days without treatment (n = 5). The error bars represent
SD, statistical significance was determined by Mann–Whitney U test: ns = non significant p > 0.05,
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
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2.5. Assessment of Her2 Status and Autophagy Marker Levels in a Treatment-Naïve EAC Patient Cohort
Our in vitro results suggest a role of autophagy in response to Her2-targeted therapy and
prompted us to investigate the relationship between basal autophagy under steady-state conditions
and Her2 status in primary resected human EAC tumor samples. The rationale for this assessment
was that amplified Her2 signaling results in increased mTORC1 signaling, leading to autophagy
suppression. To this end, we determined the Her2 status of a well-characterized treatment-naïve EAC
cohort via IHC [25]. The IHC scores for Her2 were compared to previously published scores for LC3B
and p62 [25]. Examples of LC3B and p62 IHC stainings are shown in Figure 4.
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Table 2. Results of the p62 scoring in correlation with the Her2 status.
p62
Total
Low High
Her2
negative 21 73 94
positive 3 15 18
total 24 88 112
3. Discussion
We observed induction of autophagic flux upon Lapatinib treatment in OE19 EAC cells using
two different LC3B-dependent methods for assessing autophagy. These observations are in line with
studies showing autophagy induction upon Lapatinib treatment in breast cancer [13,26]. We further
observed that OE19 cells that acquired resistance to Lapatinib exhibit a higher basal autophagy and
that the effect of autophagy induction upon Lapatinib treatment is less pronounced in these cells
compared to the normal counterpart. These findings indicate that autophagy is involved in resistance
formation against Lapatinib in EAC cells. Therefore, modulation of autophagy could potentially
be used as a mechanistic tool to overcome resistance to anticancer treatment, which represents the
most relevant clinical challenge in tumor therapy. EAC autophagy has already been reported to
enhance the efficacy of cancer therapies, and clinical trials are ongoing using hydroxychloroquine
(HCQ), an FDA-approved derivative of chloroquine used for malaria treatment, as an autophagy
inhibitor in cancer treatment. One important finding of these studies is that HCQ can be combined
with other drugs such as chemotherapies [24]. Protective autophagy and its role in the formation
of resistance to Her2-targeted treatment has been discussed for Her2-positive breast cancer in vitro
and in vivo [15,16]. Moreover, autophagy has been described as a resistance mechanism against
conventional chemotherapy in EAC cells [27].
Based on the abovementioned observations, we investigated the effect of Lapatinib in combination
with autophagy inhibitors on OE19 cell lines. We observed a reduction in relative cell viability, cell
amounts, and colony formation capacity upon these combination treatments. Using the alamarBlue®
assay, we observed a highly significant reduction of relative cell viability upon treatment with
autophagy inhibitors alone in the resistant cells, whereas these had almost no effect on the parental
cells. Looking at the cell counts of viable cells after treatment, a slightly different picture was observed.
In the resistant cells, the combination treatments were more effective than autophagy inhibition alone.
However, we observed in these cells already a significant effect (p = 0.0064) of VPS34-IN1 alone
compared to the Lapatinib treatment, whereas the autophagy inhibition alone had no significant effect
on the parental cells. The only significant reduction in colony formation capacity was seen for the
resistant cells upon combination of Lapatinib and VPS34-IN1. Taken together, these results indicate
that the resistant population of OE19 cells in general recovers better from treatment. Compared to the
parental cells, the resistant cells were generally more sensitive to the autophagy inhibitors. Especially,
the treatment of the resistant cells with VPS34-IN1 alone and in combination with Lapatinib showed
intriguing effects.
Our observations upon the combination of Lapatinib and autophagy inhibitors are in line with
other studies carried out in breast and bladder cancer models [26,28]. Both of these studies based
their conclusions mostly on results using chloroquine as an autophagy inhibitor [24]. However, it
has been shown that chloroquine does not only impair autophagic flux but also leads to multiple
cellular alterations, such as the disorganization of the Golgi and endolysosomal networks [29]. Thus,
we included in our study a promising, more specific autophagy inhibitor VPS34-IN1. This inhibitor is
highly specific for the lipid kinase VPS34, which catalyzes the phosphorylation of phosphatidylinotisol
to phosphatidylinositol 3-phosphate required for formation of new autophagosomes [23]. This early
stage autophagy inhibitor is also in preclinical development [30].
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In clinical practice, the treatment of gastric and gastroesophageal adenocarcinoma with Lapatinib
alone seems to be more challenging compared to its application in breast cancer. Particularly, it
seems that it is only suitable for a subset of patients [31,32]. We tested whether Her2 status itself
may already influence autophagy under basal conditions. In an ex vivo approach, we correlated the
Her2 status of primary resected treatment-naïve EAC tumor samples with the expression of LC3B and
p62. We found no primary correlation between the Her2 status and these autophagy-related proteins
that are widely used for approximately monitoring autophagy in tissue samples using detection by
immunohistochemistry. These results indicate that some of the tumors exhibit high while others exhibit
low levels of basal autophagy independently of the Her2 status. Regarding our in vitro results, one
could suggest that there are tumors that exhibit high basal autophagy, which would be Lapatinib
resistant and would not respond to the treatment. Unfortunately, we could not analyze tumor tissue
prior to Her2-directed treatment and compare the results of the expression analysis with response,
since gastroesophageal adenocarcinoma patients are currently only treated in a metastatic setting
outside of clinical trials. Clinically well-annotated case collections, such as the cohort of primary
resected tumors that we used for this study for studying a potential basal correlation between Her2
status and the expression of autophagy-related proteins, are not available yet.
Taken together, our study could serve as the basis for future investigations addressing resistance
mechanisms to Her2-targeted treatment in EAC. Our results indicate that autophagy could be
involved in resistance formation against Lapatinib treatment and that the combination treatment
of Her2-targeted therapy and autophagy inhibition represents a promising treatment strategy for
Her2-positive EAC patients.
4. Materials and Methods
4.1. Drugs and Inhibitors
Lapatinib (Lap) (Selleckchem, LubioScience Luzern, Switzerland, S2111) was reconstituted in
dimethyl sulfoxide (DMSO) and stock solutions were stored at −80 ◦C. Inhibitors were diluted
freshly in standard growth medium before each experiment. Chloroquine (CQ) was purchased from
Sigma-Aldrich (Buchs, Switzerland, C6628) and was dissolved in distilled water and stored at −20 ◦C.
Bafilomycin A1 (BafA) was purchased from LC Laboratories (Woburn, MA, USA, B-1080). It was
dissolved in DMSO and stored at −20 ◦C. The VPS34 inhibitor (VPS34-IN1) was purchased from
Selleckhchem (1383716-33-3), diluted in DMSO, and stored at −20 ◦C.
4.2. Cell Culture and Generation of Resistant OE19 Cells
The human EAC cancer cell line OE19 from the Public Health England Culture Collections
was purchased from Sigma-Aldrich, Buchs, Switzerland. The cells were cultured in RPMI-1640
(Sigma-Aldrich, R8758) supplemented with 10% fetal bovine serum (Sigma-Aldrich, F7524) and 1%
penicillin streptomycin (Sigma-Aldrich, P4333). Cells were kept in a humidified incubator with 5% CO2
at 37 ◦C. The human embryonic kidney cell line 293T used for lentivirus production was cultured and
maintained in DMEM (Sigma-Aldrich, D6046) supplemented with 5% FBS, 1% penicillin/streptomycin,
and 1% HEPES (Sigma-Aldrich, H3375) in a humidified incubator with 7.5% CO2 at 37 ◦C. To generate
a pool of OE19 cells showing secondary resistance to Lapatinib, OE19 P were exposed to increasing
concentrations of Lapatinib for at least 5 months. Initially, the cells were exposed to 20 nM of Lapatinib,
followed by 40, 60, 80, 100, and finally 120 nM of Lapatinib. The dosage of the drug was increased
after at least 4 weeks of treatment or after the cells were adapted to the drug. In between drug
administration, the cells were cultured in normal growth medium over the weekend. The generated
pool of resistant cells was maintained in medium with 120 nM of Lapatinib and was cultured before
the experiments in normal growth medium without the drug for 2 days.
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4.3. Western Blotting
OE19 cells were washed in phosphate buffered saline (PBS) and lysed in urea buffer (8 M urea,
0.5% triton X) containing protease inhibitor and PhosSTOP (both: Roche Diagnostics, Rotkreuz,
Switzerland). Samples were sonicated, centrifuged (13,000 rcf for 30 min), and the protein concentration
was determined via Bradford assay (BioRad, Cressier, Switzerland). Twenty micrograms of protein
were denatured in a self-made sample buffer with β-mercaptoethanol (Sigma-Aldrich, M-7522) at
95 ◦C for 5 min. Samples were loaded on a 4–20% stain-free precast gel (BioRad) and transferred onto
a polyvinylidene difluoride membrane using the Trans-Blot® Turbo™ Transfer system (BioRad). Total
protein was visualized as loading control using the ChemiDoc™ MP system (BioRad). The following
primary antibodies were used: Anti-LC3B from Novus Biologicals (rabbit polyclonal, #NB600-1384,
LuBioScience, Luzern, Switzerland) and the anti-Phospho-Her2 from Cell Signaling (rabbit monoclonal,
clone (Tyr1221/1222) (6B12), #2243P, Leiden, The Netherlands). The membranes were blocked in 5%
BSA/tris-buffered saline (TBS) for LC3B and 5% milk/TBS for Phospho-Her2. Working solutions of
the primary antibodies were prepared with a final dilution of 1:1000 in 5% milk/TBS with 0.1% Tween
(Sigma Aldrich, P9416) (TBS-T) for LC3B and 5% BSA/TBS-T for Phospho-Her2. Membranes were
incubated overnight at 4 ◦C. DyLight®650 conjugated goat anti-rabbit for LC3B (LabForce, Muttenz,
Switzerland) and respectively HRP coupled goat anti-rabbit (CellSignaling Technology, Danvers,
MA, USA) for Phospho-Her2 were used as secondary antibodies and diluted 1:1000 or 1:10,000 in
5% milk/TBS-T. Membranes were incubated for 1 h at room temperature. Proteins of interest were
visualized using the ChemiDoc™ MP system (BioRad). Bands were quantified using ImageJ software
(1.64r; NIH, Bethesda, MD, USA).
4.4. Autophagic Flux Analysis by Flow Cytometry
The mCherry-EGFP-LC3-expressing lentiviral vector was kindly provided by Dr. Maria S. Soengas
(Molecular Pathology Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain). The
vector contains a puromycin-resistant gene for selection of transduced mammalian cells. Lentivirus
production and cancer cell transduction were done as described in [33,34]. Transduced OE19 cells
were selected with puromycin (1.5 mg/mL) for 4 days. The mCherry-EGFP-LC3B-expressing cells
were seeded in 24-well flat-bottom plates at a density of 120,000 cells/well and on the next day treated
as indicated for 24 h. The FACS experiments were performed on a FACS BD LSR II (BD Biosciences,
San Jose, CA, USA) using BD FACSDiva software. The data was analyzed using FlowJo software, v10
(Ashland, OR, USA). To estimate the percentage of cells with high autophagic flux, a gate based on the
DMSO control was set as described elsewhere [22].
4.5. alamarBlue® Assay
The relative cell viability of OE19 cells after treatment was assessed using the alamarBlue® assay
(ThermoFisher Scientific, Reinach, Switzerland, DAL1100) according to the manufacturer’s instructions.
The alamarBlue® reagent consists of a redox indicator containing the dye resazurin, appearing blue
in its oxidized and red in its reduced form. Metabolically active cells catalyze the reduction of the
dye, resulting in a colorimetric change. The cells were plated in 96-well flat-bottom plates at a density
of 7000 cells/well and allowed to adhere overnight. Afterwards, the treatment was applied and the
mixture was incubated with the alamarBlue® reagent for 2 h prior to measuring absorbance at 570 and
600 nm for each indicated time point. A DMSO control was used as a reference. The reduction of the
alamarBlue® reagent was calculated and represented as relative cell viability.
4.6. Colony Forming Assay and Cell Counting
To assess the ability of cells to recover from treatment, they were treated for 48 h before
trypsinization. Then, the viable cells were counted using trypan blue with an automated cell counter
(Countess II FL, ThermoFischer Scinetific, Reinach, Switzerland). Afterwards, the cells were replated
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at equal numbers (2500 cells) in six-well plates (each condition in triplicate). After 14 days in normal
growth medium, the colonies were fixed and stained with 0.05% crystal violet in 30% ethanol. Colony
numbers were counted with GelCount™ (Oxford Optronix, Milton Park, UK).
4.7. Caspase-Glo® 3/7 Assay
The Caspase-Glo® 3/7 assay (Promega, Dübendorf, Switzerland, G8091) was used to determine
the activity of the caspases 3 and 7. Cells were seeded in white-walled 96-well flat-bottom plates
and allowed to adhere overnight. Afterwards, the cells were treated with Lapatinib at indicated
concentrations for 24 h. The Caspase-Glo® 3/7 reagent was mixed according to the manufacturer’s
instructions, added to the wells in a 2:3 ratio, and the mixture was incubated for 1 h at room temperature
in the dark. The plate was shaken for 3 s at an amplitude of 1 mm before resulting luminescent signals,
proportional to caspase activity, was measured using a luminometer (Tecan Infinite®200 PRO, Tecan,
Männedorf, Switzerland).
4.8. Statistical Analysis
All data of the in vitro experiments were expressed as mean± SD To compare differences between
groups, nonparametric Mann–Whitney U tests were applied using the Prism software. A p-value < 0.05
was considered statistically significant.
For correlative statistical analysis of the immunohistochemical stainings, IBM SPPS Statistics 24
(IBM Corporation, Armonk, NY, USA) was used. Group comparisons were performed using crosstabs,
χ-squared tests, and Fisher’s exact tests. The significance level was set for a p-value of <0.05.
4.9. Patients and Tissue Samples
Formalin fixed, paraffin embedded (FFPE) tumor tissue from 112 esophageal adenocarcinoma
patients was used to generate a tissue microarray (TMA). Tumors of all stages were included. The
tumors were all primary resected without prior neoadjuvant chemotherapy, radiochemotherapy, or
Her2-directed treatment, respectively. Details of the case collection have been described before [25].
The use of human archival pathological tissue for TMA-based studies was approved by the local ethics
committee (Kantonale Ethikkommission Bern, Switzerland, 200/14; approved 17 February 2015).
4.10. Immunohistochemistry for FFPE Tumor Tissue
Immunohistochemical stainings were performed on 4-µm sections of the tissue microarray using
automatic immunostainers. IHC for Her2 (clone 4B5, Ventana Roche, Rotkreuz, Switzerland) was
performed using the Benchmark Ultra immunostainer (Ventana Roche), undiluted, with EDTA antigen
retrieval for 36 min. IHC for LC3B and p62 was performed using the Leica Bond RX immunostainer
(Leica Biosystems, Muttenz, Switzerland) as described in detail before [35]: briefly, the anti-LC3B
antibody (Novus Biologicals #NB600-1384) was diluted 1:4000 and incubated at 95 ◦C for 30 min. The
anti-p62/SQSTM1 antibody (MBL rabbit polyclonal, #PM0045, LabForce, Nunningen, Switzerland)
was diluted 1:9000 and incubated at 95 ◦C for 30 min. The Bond Polymer Refine Detection kit (Leica
Biosystems, DS9800) and the Ultra view DAB detection kit (Ventana Roche) were used for visualization
according to the instructions of the manufacturer. Scoring of immunohistochemical staining patterns
for LC3B and p62 and categorization into high and low expression were performed as described in
detail before for this patient cohort [25]. Scoring was performed by one experienced pathologist (RL).
4.11. Evaluation of Her2 Status and Classification of Her2-Positive Tumors
Evaluation of Her2 was carried out according to published guidelines by RL [36]. The classification
of tumors into Her2 negative (score 0 and 1) and Her2 positive (score 2 and 3) was performed as
described elsewhere [37].
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5. Conclusions
To our knowledge, we are the first to show induction of autophagic flux upon Lapatinib treatment
in esophageal adenocarcinoma cells. Furthermore, we observed an elevated basal autophagic
flux as well as a more pronounced upregulation of autophagic flux upon Lapatinib treatment in
Lapatinib-resistant EAC cells. By combining Lapatinib with autophagy inhibition, we observed
a significant effect on cell viability in parental and resistant cells, whereby the effect was more
pronounced in resistant cells. In addition, we assessed the regeneration capacity of the tumor
cells after single and double treatments using a colony formation assay. The parental cells did
not show a significant reduction of colonies in response to the autophagy inhibitors alone but
responded to Lapatinib treatment alone or in combination with autophagy inhibitors. Importantly,
Lapatinib-resistant EAC cells showed a significant reduction in colony formation capacity only when
treated with VPS34-IN1 and Lapatinib. As for the ex vivo data, we observed no correlation between
the autophagy markers LC3B and p62 and the Her2 status of EAC cases in a treatment-naïve setting.
Currently, we do not have access to tissue samples of EAC patients who were treated with Lapatinib
and can therefore not analyze our results in the context of treatment resistance. Nevertheless, we
speculate that autophagy marker levels could be associated with treatment resistance respectively
with responsiveness.
Overall, we showed a beneficial effect of the combination treatment with Lapatinib and autophagy
inhibition on Her2-inhibitor sensitive as well as resistant OE19 EAC cells. Reviewing our results,
we propose that autophagy may contribute to acquired resistance to Her2-targeted therapy in EAC,
and that combining Her2 and early autophagy inhibition might be a future treatment option for
EAC patients.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/10/
3069/s1.
Author Contributions: F.A.J., O.A., V.B., and A.M.S. designed and performed the experimental research.
Resources, investigation, and data curation by B.D., C.A.S., D.K., and R.L. M.P.T. and R.L. designed the project,
analyzed data, wrote the paper, and gave final approval of the submitted manuscript. All authors have approved
the manuscript.
Funding: The study was supported by grants from the Bernese Cancer League awarded to B.D. and the Swiss
Cancer League (KFS-3700-08-2015) awarded to R.L and M.P.T.
Acknowledgments: The authors thank Deborah Krauer for her excellent technical assistance. The authors
acknowledge the Translational Research Unit (TRU) of the Institute of Pathology, University of Bern for the
excellent technical support on this project. We thank the Tissue Bank Bern at the Institute of Pathology, University
of Bern in acquiring patient tissue, and the Cancer Registry Bern for support acquiring survival data. The
authors also deeply thank Maria S. Soengas (Molecular Pathology Program, Centro Nacional de Investigaciones
Oncologicas, Madrid, Spain) for providing the mCherry-EGFP-LC3-expressing lentiviral vector.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to
publish the results.
References
1. Lagergren, J.; Smyth, E.; Cunningham, D.; Lagergren, P. Oesophageal cancer. Lancet 2017, 390, 2383–2396.
[CrossRef]
2. Coleman, H.G.; Xie, S.-H.; Lagergren, J. The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology
2018, 154, 390–405. [CrossRef] [PubMed]
3. Dulak, A.M.; Stojanov, P.; Peng, S.; Lawrence, M.S.; Fox, C.; Stewart, C.; Bandla, S.; Imamura, Y.;
Schumacher, S.E.; Shefler, E.; et al. Exome and whole-genome sequencing of esophageal adenocarcinoma
identifies recurrent driver events and mutational complexity. Nat. Genet. 2013, 45, 478–486. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2018, 19, 3069 13 of 14
4. Bang, Y.-J.; Van Cutsem, E.; Feyereislova, A.; Chung, H.C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.;
Omuro, Y.; Satoh, T.; et al. ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer
(ToGA): A phase 3, open-label, randomised controlled trial. Lancet Lond. Engl. 2010, 376, 687–697. [CrossRef]
5. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric
adenocarcinoma. Nature 2014, 513, 202–209. [CrossRef] [PubMed]
6. Yarden, Y.; Pines, G. The ERBB network: At last, cancer therapy meets systems biology. Nat. Rev. Cancer
2012, 12, 553–563. [CrossRef] [PubMed]
7. Gerson, J.N.; Skariah, S.; Denlinger, C.S.; Astsaturov, I. Perspectives of HER2-targeting in gastric and
esophageal cancer. Expert Opin. Investig. Drugs 2017, 26, 531–540. [CrossRef] [PubMed]
8. Dikic, I.; Elazar, Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol.
2018, 19, 349–364. [CrossRef] [PubMed]
9. Galluzzi, L.; Baehrecke, E.H.; Ballabio, A.; Boya, P.; Bravo-San Pedro, J.M.; Cecconi, F.; Choi, A.M.; Chu, C.T.;
Codogno, P.; Colombo, M.I.; et al. Molecular definitions of autophagy and related processes. EMBO J. 2017,
36, 1811–1836. [CrossRef] [PubMed]
10. Galluzzi, L.; Pietrocola, F.; Bravo-San Pedro, J.M.; Amaravadi, R.K.; Baehrecke, E.H.; Cecconi, F.; Codogno, P.;
Debnath, J.; Gewirtz, D.A.; Karantza, V.; et al. Autophagy in malignant transformation and cancer
progression. EMBO J. 2015, 34, 856–880. [CrossRef] [PubMed]
11. Galluzzi, L.; Pedro, J.M.B.-S.; Kroemer, G. Defective Autophagy Initiates Malignant Transformation. Mol. Cell
2016, 62, 473–474. [CrossRef] [PubMed]
12. Jung, C.H.; Ro, S.-H.; Cao, J.; Otto, N.M.; Kim, D.-H. mTOR regulation of autophagy. FEBS Lett. 2010, 584,
1287–1295. [CrossRef] [PubMed]
13. Cufí, S.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Corominas-Faja, B.; Urruticoechea, A.; Martin-Castillo, B.;
Menendez, J.A. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to
HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast
cancer treatment. Oncotarget 2012, 3, 1600–1614. [CrossRef] [PubMed]
14. Rodríguez, C.E.; Reidel, S.I.; Bal de Kier Joffé, E.D.; Jasnis, M.A.; Fiszman, G.L. Autophagy Protects from
Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids. PLoS ONE 2015, 10,
e0137920. [CrossRef] [PubMed]
15. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Menendez, J.A. Autophagy facilitates the development of breast
cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS ONE 2009, 4, e6251. [CrossRef]
[PubMed]
16. Zhu, X.; Wu, L.; Qiao, H.; Han, T.; Chen, S.; Liu, X.; Jiang, R.; Wei, Y.; Feng, D.; Zhang, Y.; et al. Autophagy
stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib. J. Cell. Biochem. 2013, 114,
2643–2653. [CrossRef] [PubMed]
17. Lordick, F.; Mariette, C.; Haustermans, K.; Obermannová, R.; Arnold, D. ESMO Guidelines Committee
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2016, 27, v50–v57. [CrossRef] [PubMed]
18. Wetterskog, D.; Shiu, K.-K.; Chong, I.; Meijer, T.; Mackay, A.; Lambros, M.; Cunningham, D.; Reis-Filho, J.S.;
Lord, C.J.; Ashworth, A. Identification of novel determinants of resistance to lapatinib in ERBB2-amplified
cancers. Oncogene 2014, 33, 966–976. [CrossRef] [PubMed]
19. Fichter, C.D.; Timme, S.; Braun, J.A.; Gudernatsch, V.; Schöpflin, A.; Bogatyreva, L.; Geddert, H.; Faller, G.;
Klimstra, D.; Tang, L.; et al. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two
histotypes of esophageal cancer. Int. J. Cancer 2014, 135, 1517–1530. [CrossRef] [PubMed]
20. Dahlberg, P.S.; Jacobson, B.A.; Dahal, G.; Fink, J.M.; Kratzke, R.A.; Maddaus, M.A.; Ferrin, L.J. ERBB2
amplifications in esophageal adenocarcinoma. Ann. Thorac. Surg. 2004, 78, 1790–1800. [CrossRef] [PubMed]
21. Langer, R.; Rauser, S.; Feith, M.; Nährig, J.M.; Feuchtinger, A.; Friess, H.; Höfler, H.; Walch, A. Assessment of
ErbB2 (Her2) in oesophageal adenocarcinomas: Summary of a revised immunohistochemical evaluation
system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod. Pathol. Off. J. U.
S. Can. Acad. Pathol. Inc 2011, 24, 908–916. [CrossRef] [PubMed]
22. Gump, J.M.; Thorburn, A. Sorting cells for basal and induced autophagic flux by quantitative ratiometric
flow cytometry. Autophagy 2014, 10, 1327–1334. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3069 14 of 14
23. Bago, R.; Malik, N.; Munson, M.J.; Prescott, A.R.; Davies, P.; Sommer, E.; Shpiro, N.; Ward, R.;
Cross, D.; Ganley, I.G.; et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that
the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III
phosphoinositide 3-kinase. Biochem. J. 2014, 463, 413–427. [CrossRef] [PubMed]
24. Chude, C.I.; Amaravadi, R.K. Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors.
Int. J. Mol. Sci. 2017, 18, 1279. [CrossRef] [PubMed]
25. Adams, O.; Dislich, B.; Berezowska, S.; Schläfli, A.M.; Seiler, C.A.; Kröll, D.; Tschan, M.P.; Langer, R.
Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas. Oncotarget 2016,
7, 39241–39255. [CrossRef] [PubMed]
26. Chen, S.; Zhu, X.; Qiao, H.; Ye, M.; Lai, X.; Yu, S.; Ding, L.; Wen, A.; Zhang, J. Protective autophagy promotes
the resistance of HER2-positive breast cancer cells to lapatinib. Tumour Biol. J. Int. Soc. Oncodevelopmental
Biol. Med. 2016, 37, 2321–2331. [CrossRef] [PubMed]
27. O’Donovan, T.R.; O’Sullivan, G.C.; McKenna, S.L. Induction of autophagy by drug-resistant esophageal
cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy
2011, 7, 509–524. [CrossRef] [PubMed]
28. Kang, M.; Lee, K.-H.; Lee, H.S.; Jeong, C.W.; Kwak, C.; Kim, H.H.; Ku, J.H. Concurrent Autophagy Inhibition
Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human
Bladder Cancer Cells. Int. J. Mol. Sci. 2017, 18, 321. [CrossRef] [PubMed]
29. Mauthe, M.; Orhon, I.; Rocchi, C.; Zhou, X.; Luhr, M.; Hijlkema, K.-J.; Coppes, R.P.; Engedal, N.; Mari, M.;
Reggiori, F. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy
2018, 14, 1435–1455. [CrossRef] [PubMed]
30. Galluzzi, L.; Bravo-San Pedro, J.M.; Levine, B.; Green, D.R.; Kroemer, G. Pharmacological modulation
of autophagy: Therapeutic potential and persisting obstacles. Nat. Rev. Drug Discov. 2017, 16, 487–511.
[CrossRef] [PubMed]
31. Schulze, A.B.; Kerkhoff, A.; Lenz, G.; Kessler, T. Targeted therapies of HER2-positive gastric adenocarcinoma.
Transl. Cancer Res. 2017, 6, S1177–S1180. [CrossRef]
32. Curea, F.G.; Hebbar, M.; Ilie, S.M.; Bacinschi, X.E.; Trifanescu, O.G.; Botnariuc, I.; Anghel, R.M. Current
Targeted Therapies in HER2-Positive Gastric Adenocarcinoma. Cancer Biother. Radiopharm. 2017, 32, 351–363.
[CrossRef] [PubMed]
33. Rizzi, M.; Tschan, M.P.; Britschgi, C.; Britschgi, A.; Hügli, B.; Grob, T.J.; Leupin, N.; Mueller, B.U.;
Simon, H.-U.; Ziemiecki, A.; et al. The death-associated protein kinase 2 is up-regulated during normal
myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells. J. Leukoc. Biol. 2007,
81, 1599–1608. [CrossRef] [PubMed]
34. Tschan, M.P.; Fischer, K.M.; Fung, V.S.; Pirnia, F.; Borner, M.M.; Fey, M.F.; Tobler, A.; Torbett, B.E. Alternative
splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that
alters macrophage differentiation patterns. J. Biol. Chem. 2003, 278, 42750–42760. [CrossRef] [PubMed]
35. Schläfli, A.M.; Berezowska, S.; Adams, O.; Langer, R.; Tschan, M.P. Reliable LC3 and p62 autophagy marker
detection in formalin fixed paraffin embedded human tissue by immunohistochemistry. Eur. J. Histochem.
2015, 59, 2481. [CrossRef] [PubMed]
36. Hofmann, M.; Stoss, O.; Shi, D.; Büttner, R.; Vijver, M.V.D.; Kim, W.; Ochiai, A.; Rüschoff, J.; Henkel, T.
Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology
2008, 52, 797–805. [CrossRef] [PubMed]
37. Tominaga, N.; Gotoda, T.; Hara, M.; Hale, M.D.; Tsuchiya, T.; Matsubayashi, J.; Kono, S.; Kusano, C.; Itoi, T.;
Fujimoto, K.; et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2
protein expression status in gastric cancer. Gastric Cancer 2016, 19, 553–560. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
